The in vitro susceptibility of 20 isolates of Clostridium difficile to cefotaxime, moxalactam, and cefoperazone was determined by a standard agar dilution method. The median minimal inhibitory concentrations were 64, 32, and 32 ,ug/ml for cefotaxime, moxalactam, and cefoperazone, respectively.
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Clostridium difficile-induced diarrhea is a serious complication of antimicrobial chemotherapy. Many antimicrobial agents have been associated with the disease, with clindamycin and ampicillin most commonly cited (7) . In addition, several recent reports have emphasized cephalosporin-associated diarrhea and colitis induced by C. dafficile (2, 3, 12, 17 Twenty strains of C. difficile were studied. All were obtained from stools of patients suspected of having antibiotic-associated diarrhea or colitis and therefore submitted to the Wisconsin State Laboratory of Hygiene for evaluation for the presence of C. difficile and its toxin. There was no discernible clustering of sources of these specimens. The initial stool samples were cultured by modification of a previously described technique on CCFA agar (9) . Organisms with the typical colonial morphology of C. difficile were isolated and identified by a standard technique (11) . All isolates were found to produce a cytopathic toxin that was neutralized by C. difficile antitoxin (purchased from T. Wilkins, Virginia Polytechnic Institute) when tested by a modification of the method of Aswell et al. (1) (16) . If a minimal inhibitory concentration of 16 ,g/ ml is used as the cutoff point for susceptibility to these drugs, then essentially all isolates tested would be considered either intermediately sensitive or resistant to all three of these drugs. This would seem to predict that none of these agents would inhibit C. difficile growth, so that toxin elaboration and production of diarrhea or colitis (or both) would be possible. However, as has been previously noted (5, 8) , the mechanism of production of C. difficile-induced diarrhea is more complicated than a simple superinfection with drug-resistant C. difficile.
Furthermore, susceptibility to a given drug is generally based on achievable serum levels, whereas susceptibility to fecal drug levels may be more important in the pathogenesis of C.
difficile-induced diarrhea (5, 8) . To our knowledge, there are no available published data on fecal levels of these drugs. Pharmacokinetic differences among these agents (4, 13, 14) predict higher fecal concentrations of cefoperazone with similar parenteral dosage, because biliary excretion is the primary route of elimination. We have recently found fecal concentrations of cefoperazone up to 160 FLg/g even in patients with impaired biiary clearance of the drug (Craig, unpublished observations). Thus, inhibitory levels of cefoperazone may be achieved in feces.
Further studies are needed to clarify the relationship between the minimal inhibitory concentration of newer antimicrobial agents for C. difficile and the propensity of these agents to produce C. difficile-induced diarrheal diseases.
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